ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 40676293

PI3 K/AKT/mTOR pathway and its role in breast cancer stem cells.

Prabhu KS and 7 others. Naunyn Schmiedebergs Arch Pharmacol, 2025. Cited by 13 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. PI3 K/AKT/mTOR pathway and its role in breast cancer stem cells. Papers, record 40676293. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40676293

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
PI3 K/AKT/mTOR pathway and its role in breast cancer stem cells.
PubMed
Journal
Naunyn Schmiedebergs Arch Pharmacol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
3.92, provisional
iCite
Revised in PubMed
2026-07-13
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Prabhu KSKirti S
2Kuttikrishnan SShilpa
3Mariyam ZZahwa
4Habeeba UUmmu
5Panicker AJAnu Jayanthi
6Masoodi TTariq
7Junejo KKulsoom
8Uddin SShahab

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Neoplastic Stem CellsMajor topic
TOR Serine-Threonine KinasesMajor topic
Breast NeoplasmsMajor topic
Proto-Oncogene Proteins c-aktMajor topic
Phosphatidylinositol 3-KinasesMajor topic
Humans
Signal Transduction
Female
Animals
Antineoplastic Agents

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
IRGC-05-SI-18-307Hamad Medical CorporationPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References176

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132,296,634PI(3,4)P2 Signaling in Cancer and Metabolism.Front Oncol2020https://conductscience.org/library/papers/32296634PubMed
29,593,664The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.J Biol Chem1998https://conductscience.org/library/papers/9593664PubMed
336,853,294Evaluation of LGR5 Cancer Stem Cell Marker Expression in Breast Cancer and Its Relationship with Hormonal Profile and Clinical Pathological Features.Asian Pac J Cancer Prev2023https://conductscience.org/library/papers/36853294PubMed
438,201,468The Role of Cancer Stem Cell Markers in Ovarian Cancer.Cancers (Basel)2023https://conductscience.org/library/papers/38201468PubMed
537,832,401Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer.Biomed Pharmacother2023https://conductscience.org/library/papers/37832401PubMed
629,473,320Epigenetic silencing of RNF144A expression in breast cancer cells through promoter hypermethylation and MBD4.Cancer Med2018https://conductscience.org/library/papers/29473320PubMed
734,050,189Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge.NPJ Breast Cancer2021https://conductscience.org/library/papers/34050189PubMed
826,002,111Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.Lancet2015https://conductscience.org/library/papers/26002111PubMed
930,220,190Immunohistochemical Expression of Nanog and Its Relation with Clinicopathologic Characteristics in Breast Ductal CarcinomaIran Biomed J2019https://conductscience.org/library/papers/30220190PubMed
1018,485,877The epithelial-mesenchymal transition generates cells with properties of stem cells.Cell2008https://conductscience.org/library/papers/18485877PubMed

1 to 10 of 176

See all 176 references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
42,857,018Beyond molecular classification: integrating signaling, subcellular, and immune reprogramming in endometrial cancer.Front Oncol2026https://conductscience.org/library/papers/42857018PubMed
42,744,971Integrated expression profiling reveals molecular crosstalk between CFTR, FASN, FRAP (mTOR), and BANK1 in hepatocellular carcinoma.Sci Rep2026https://conductscience.org/library/papers/42744971PubMed
42,650,882Diet and Lipidomics Mediated Regulation of Mesenchymal Stem Cell Function: Diet, Omics and Stem Cell Connection.Biomolecules2026https://conductscience.org/library/papers/42650882PubMed
42,650,747Does the ERBB/EGF Signaling Network Serve as a Nexus for Oncogenic Signals in Uveal Melanoma?Biomolecules2026https://conductscience.org/library/papers/42650747PubMed
42,403,503The Interaction of PI3K/AKT/mTOR Pathway with the Tumor Microenvironment: A Dual Engine Driving Breast Cancer Progression and Reshaping Treatment Strategies.Cancer Manag Res2026https://conductscience.org/library/papers/42403503PubMed
42,337,925Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications.Cancer Med2026https://conductscience.org/library/papers/42337925PubMed
42,062,942Integrated molecular pathology and therapeutic outcomes in dermatofibrosarcoma protuberans: Ki-67, COL1A1::PDGFB, and efficacy of Mohs surgery with postoperative imatinib in 153 Chinese patients.BMC Cancer2026https://conductscience.org/library/papers/42062942PubMed
42,041,716
Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review.
Curr Oncol2026https://conductscience.org/library/papers/42041716PubMed
41,972,545Decoding the Clinical and Therapeutic Significance of MEAK7 in Triple-Negative Breast Cancer Through Integrative Bioinformatics.Biology (Basel)2026https://conductscience.org/library/papers/41972545PubMed
41,928,774Phosphoinositide-dependent kinase 1 (PDK1) in cancer: molecular insights and therapeutic strategies.Front Chem2026https://conductscience.org/library/papers/41928774PubMed

1 to 10 of 13

See all 13 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
MTOR2,475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
PIK3CB5,291PubTator's text mininghttps://conductscience.org/library/genes/5291NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40676293

GET https://conductscience.org/api/papers/v1/40676293/references?page=2

API referenceFor AI assistants